Erlotinib Recruiting Phase 4 Trials for Lung Cancer Non-Small Cell Cancer (NSCLC) Treatment

IndicationsStatusPurposePhase
RecruitingTreatment4
clinicaltrials.gov IdentifierTitleDrugs
NCT03460678Randomized Comparative Study of Erlotinib and Pemetrexed in the Maintenance Treatment of Advanced Lung Cancer Patients.
NCT02031601Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer